Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by eric40on Feb 19, 2018 11:54pm
542 Views
Post# 27585524

Some more info about IAIP from Fred.

Some more info about IAIP from Fred.

I asked a couple of questions to Fred about IAIP. Here is a resume of it.

 

Prometic can already extract IAIP from Plasma with PPPS. I mean, the resin is ready and fully functional for the PPPS process.

 

As for plasminogen, Prometic will probably be the only one in the world to be able to extract IAIP in commercial quantity with PPPS.

 

The partnership with Prothera from November, 19, 2015 excluded two orphan indications with IAIP and NEC is one of the two. So Prometic owned 100% of the profits from IAIP for  NEC including also 100% of the very possible pediatric voucher.

 

They expect the IND for IAIP for NEC to be in 2019.

 

It will probably have a fast track designation according to Fred.

 

The clinical trial will consist in bringing the normal level of IAIP for the premature baby affected with NEC. Basically, they will mesure the level of IAIP of the premature baby with NEC then inject IAIP IV in order to bring and keep the normal level of IAIP in order to cure NEC.

 

So it will be a very similar procedure as Pg clinical trial.

But with IAIP for NEC, the market is much bigger than PgCD and the Pediatric Voucher is probably 100% considering that the patients are premature baby and NEC is highly lifetreatening.

Still a couple of years but great pipeline

 

 

 


Bullboard Posts